| Host: |
Rabbit |
| Applications: |
WB/IHC/IF |
| Reactivity: |
Human/Mouse/Rat |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Rabbit polyclonal antibody anti-SIAH1 (1-313) is suitable for use in Western Blot, Immunohistochemistry and Immunofluorescence research applications. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
PBS with 0.01% Thimerosal, 50% Glycerol, pH7.3. |
| Purification: |
Affinity purification |
| Dilution Range: |
WB 1:500-1:2000IHC-P 1:50-1:200IF/ICC 1:50-1:200 |
| Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Gene Symbol: |
SIAH1 |
| Gene ID: |
6477 |
| Uniprot ID: |
SIAH1_HUMAN |
| Immunogen Region: |
1-313 |
| Immunogen: |
Recombinant fusion protein containing a sequence corresponding to amino acids 1-313 of human SIAH1 (NP_001006611.1). |
| Immunogen Sequence: |
MTGKATPPSLYSWRGVLFTC LPAARTRKRKEMSRQTATAL PTGTSKCPPSQRVPALTGTT ASNNDLASLFECPVCFDYVL PPILQCQSGHLVCSNCRPKL TCCPTCRGPLGSIRNLAMEK VANSVLFPCKYASSGCEITL PHTEKADHEELCEFRPYSCP CPGASCKWQGSLDAVMPHLM HQHKSITTLQGEDIVFLATD INLPGAVDWVMMQSCFGFHF MLVLEKQEKYDGHQQFFAI |
| Tissue Specificity | Widely expressed at a low level. Down-regulated in advanced hepatocellular carcinomas. |
| Post Translational Modifications | Phosphorylated on Ser-19 by ATM and ATR. This phosphorylation disrupts SIAH1 interaction with HIPK2, and subsequent proteasomal degradation of HIPK2. |
| Function | E3 ubiquitin-protein ligase that mediates ubiquitination and subsequent proteasomal degradation of target proteins. E3 ubiquitin ligases accept ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates. Mediates E3 ubiquitin ligase activity either through direct binding to substrates or by functioning as the essential RING domain subunit of larger E3 complexes. Triggers the ubiquitin-mediated degradation of many substrates, including proteins involved in transcription regulation (ELL2, MYB, POU2AF1, PML and RBBP8), a cell surface receptor (DCC), the cell-surface receptor-type tyrosine kinase FLT3, the cytoplasmic signal transduction molecules (KLF10/TIEG1 and NUMB), an antiapoptotic protein (BAG1), a microtubule motor protein (KIF22), a protein involved in synaptic vesicle function in neurons (SYP), a structural protein (CTNNB1) and SNCAIP. Confers constitutive instability to HIPK2 through proteasomal degradation. It is thereby involved in many cellular processes such as apoptosis, tumor suppression, cell cycle, axon guidance, transcription regulation, spermatogenesis and TNF-alpha signaling. Has some overlapping function with SIAH2. Induces apoptosis in cooperation with PEG3. Upon nitric oxid (NO) generation that follows apoptotic stimulation, interacts with S-nitrosylated GAPDH, mediating the translocation of GAPDH to the nucleus. GAPDH acts as a stabilizer of SIAH1, facilitating the degradation of nuclear proteins. Mediates ubiquitination and degradation of EGLN2 and EGLN3 in response to the unfolded protein response (UPR), leading to their degradation and subsequent stabilization of ATF4. Also part of the Wnt signaling pathway in which it mediates the Wnt-induced ubiquitin-mediated proteasomal degradation of AXIN1. |
| Protein Name | E3 Ubiquitin-Protein Ligase Siah1Ring-Type E3 Ubiquitin Transferase Siah1Seven In Absentia Homolog 1Siah-1Siah-1a |
| Database Links | Reactome: R-HSA-373752Reactome: R-HSA-977225Reactome: R-HSA-983168 |
| Cellular Localisation | CytoplasmNucleusPredominantly CytoplasmicPartially Nuclear |
| Alternative Antibody Names | Anti-E3 Ubiquitin-Protein Ligase Siah1 antibodyAnti-Ring-Type E3 Ubiquitin Transferase Siah1 antibodyAnti-Seven In Absentia Homolog 1 antibodyAnti-Siah-1 antibodyAnti-Siah-1a antibodyAnti-SIAH1 antibodyAnti-HUMSIAH antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
